Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
10:56am, Thursday, 13'th Nov 2025
The consensus price target hints at a 62.8% upside potential for Nektar (NKTR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets
10:59am, Wednesday, 12'th Nov 2025
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Der
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout
12:39am, Wednesday, 12'th Nov 2025
Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing R
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dos
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
04:26pm, Friday, 07'th Nov 2025
Nektar Therapeutics ( NKTR ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Vivian Wu Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Resea
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
11:16am, Friday, 07'th Nov 2025
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates
06:56pm, Thursday, 06'th Nov 2025
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago.
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
04:15pm, Thursday, 06'th Nov 2025
SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable se
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
06:00pm, Thursday, 30'th Oct 2025
SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Confe
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 30'th Oct 2025
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-ba
Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?
10:55am, Tuesday, 28'th Oct 2025
The mean of analysts' price targets for Nektar (NKTR) points to a 50% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonis
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
08:37am, Monday, 13'th Oct 2025
Nektar Therapeutics (NKTR -2.34%) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January.
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
08:41am, Sunday, 05'th Oct 2025
Shares of Nektar Therapeutics (NKTR 0.08%), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly enthusias
